INTS
Intensity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
Hanging Man
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INTS
Intensity Therapeutics, Inc.
A clinical-stage biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer.
Biological Technology
11/30/2012
06/30/2023
NASDAQ Stock Exchange
5
12-31
Common stock
1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779
--
Intensity Therapeutics, Inc., was incorporated in Delaware on November 30, 2012. The company is a clinical-stage biotechnology company that has pioneered a new immune-based approach to the treatment of solid tumor cancers. The company uses its DfuseRx technology platform to create patented drug formulations that, after direct injection, rapidly spread throughout the tumor and the therapeutic agent into cancer cells. The company's product candidate has the potential to induce an adaptive immune response that can attack not only injected tumors but also uninjected tumors. The company's main product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer.
Company Financials
EPS
INTS has released its 2025 Q3 earnings. EPS was reported at -0.06, versus the expected -0.06, meeting expectations. The chart below visualizes how INTS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
